At its final monthly meeting in London, the European Medicines Agency’s drug evaluation committee, the CHMP, gave the all-clear to all eight of the new drugs that were up for an opinion on EU marketing approval.
They included treatments for rare diseases with no available therapies, while three products were recommended for a conditional marketing authorization...